非布索坦可根治痛风吗？

It is a new and highly effective selective inhibitor of non-purine xanthine oxidase (a key enzyme that promotes uric acid production). Febuxostat is the latest XOR inhibitor developed in the world. It acts highly selectively on this oxidase to reduce the synthesis of uric acid in the body and lower the concentration of uric acid, thereby effectively treating gout. Today we will learn about whether febuxostat can cure gout?

Among drugs that inhibit uric acid production, colchicine is mainly used in the acute phase (acute phase). Compared with febuxostat, it is mainly allopurinol. Compared with allopurinol, febuxostat has the following advantages in addition to having fewer side effects:

1. Allopurinol only inhibits the reduced form of XOR, while febuxostat has a significant inhibitory effect on both oxidized and reduced forms of XOR, so its uric acid-lowering effect is more powerful and lasting;

   2. Since allopurinol is a purine analogue, it will inevitably affect the activities of other enzymes involved in purine and pyridine metabolism. Therefore, repeated high-dose administration is required to maintain high drug levels during allopurinol treatment. This also leads to serious or even fatal adverse reactions due to drug accumulation. Febuxostat is a non-purine XOR inhibitor and therefore has a better safety profile.

Febuxostat can reduce the level of uric acid in the blood of gout patients with hyperuricemia. The dosage of Febuxostat is 40 mg or 80 mg once daily, but this product is not recommended for gout patients without hyperuricemia.

Gout occurs due to excessive production of uric acid in the body and reduced kidney clearance ability. Uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs. Therefore, the usual treatment for gout is to promote uric acid excretion and inhibit uric acid production, and take appropriate measures to improve related symptoms.

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of febuxostat in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, it was found that the serum uric acid concentration of patients in each dose group of this product was significantly lower than before treatment, with an average reduction of 37%, 44% and 59% in each group from low to high dose, while patients in the placebo group only decreased by 2%;

The above is the content of treating gout, I hope it can help you!